影視股午後直線拉昇 中國2月票房超122億創新高
格隆匯3月1日丨影視股午後集體走強,影視指數直線拉昇一度漲近2%,個股方面,上海電影、金逸影視、萬達電影、中國電影、北京文化、華誼兄弟、橫店影視等拉昇明顯。數據顯示,2021年2月票房共計122.67億,相較2019年2月創下的內地單月最高票房紀錄提升了11億元,創全球單月大盤紀錄新高,比北美單月最高紀錄高出約5億美元。2月累計觀影人次達2.66億,與18年同期持平。月票房前三分別為《你好,李煥英》、《唐探3》和《刺殺小説家》。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.